New England Cancer Specialists is offering eligible patients dealing with metastatic pancreatic cancer access to a new therapy that could provide another option when cancer has progressed despite previous treatments.
By way of an expanded access program, NECS is making available the investigational oral inhibitor daraxonrasib, for eligible patients with pancreatic ductal adenocarcinoma, as a clinical trial.
New England Cancer Specialists, with locations in Maine at Rock Row in Westbrook, Kennebunk and Topsham, is the largest independent oncology practice north of Boston, providing comprehensive care including oncology, hematology, radiation oncology, breast health and surgery, genetic counseling, supportive care, survivorship services, precision medicine and a robust clinical research program.
A statement from NECS noted that the therapy has recently been publicized as being helpful in treating former U.S. Sen. Ben Sasse, R-Neb.
Pancreatic cancer is one of the most challenging cancers to treat, and often spreads to other parts of the body.
“Patients with metastatic pancreatic cancer urgently need additional treatment options, particularly when their disease progresses after initial therapy,” said Dr. Matthew Dugan, an oncologist at NECS.
“Expanded access to daraxonrasib gives our multidisciplinary team another potential option to evaluate for appropriately selected patients while the drug remains under regulatory review,” Dugan added.
A study published in the New England Journal of Medicine in May 2026, found that metastatic patients treated with daraxonrasib demonstrated a median overall survival of 13.2 months compared with 6.7 months for chemotherapy.
Daraxonrasib is an investigational medicine and has not yet been approved by the FDA for the treatment of pancreatic cancer. Regulatory review is ongoing.
Patients and families interested in learning whether daraxonrasib may be an option are encouraged to speak with their treating oncologist or contact NECS.
